Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC)
AffiliationVisible Analytics, Reading, UK. Visible Analytics, Oxford, UK. Visible Analytics, Budapest, Hungary. Health Economics, Pricing, Reimbursement & Market Access, SIRTEX Medical United Kingdom Ltd, London, UK. Department of Medical Oncology, Guy's & St Thomas' Nhs Foundation Trust, London, UK. Department of Radiology, The Christie NHS Foundation Trust, Manchester, UK.
MetadataShow full item record
AbstractIntroduction: While essential for cost-effectiveness analyses, there are no current resource use and cost data available for advanced hepatocellular carcinoma (HCC) and selective internal radiation therapy (SIRT). The study aims to assess current resource use and costs in HCC and for SIRT compared to historical survey data. Areas covered: To address this data gap, resource use was elicited via surveys and interviews with medical professionals experienced with HCC and SIRT in the United Kingdom. Unit costs were from publicly available databases. Resource use and costs were estimated and compared to prior surveys. Expert opinion: From eleven responses, pre-progression costs for SIRT and systemic therapy were £256.77 and £292.27/month, respectively. One-off progression and post-progression costs were £209.98 and £522.84/month. Monthly costs were 54%-79% lower than in previous surveys, due to reduction in hospitalizations and funded social care. Furthermore, substantial differences in resource use associated with SIRT between clinical practice and clinical trials were found. In conclusion, increased availability and familiarity with systemic treatments has led to important changes in HCC care and SIRT administration. The uncertainty from the use of expert opinion and the limited number of hospitals with SIRT experience can be addressed with future research using large databases, registries.
CitationMuszbek N, Evans R, Remak E, Brennan VK, Colaone F, Shergill S, et al. Changes in treatment pattern and costs in advanced hepatocellular carcinoma (HCC). Expert Review of Pharmacoeconomics & Outcomes Research. 2021 Sep 6;1–8.
JournalExpert Review of Pharmacoeconomics and Outcomes Research
- A cost analysis of SIR-Spheres yttrium-90 resin microspheres versus tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma in France, Italy, Spain and the UK.
- Authors: Pollock RF, Colaone F, Guardiola L, Shergill S, Brennan VK
- Issue date: 2020 Jun
- Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma.
- Authors: Ricke J, Klümpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, Gasbarrini A, Pech M, Peck-Radosavljevic M, Popovič P, Rosmorduc O, Schott E, Seidensticker M, Verslype C, Sangro B, Malfertheiner P
- Issue date: 2019 Dec
- Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
- Authors: Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G, SARAH Trial Group
- Issue date: 2017 Dec
- Treatment options for unresectable HCC with a focus on SIRT with Yttrium-90 resin microspheres.
- Authors: Wang EA, Stein JP, Bellavia RJ, Broadwell SR
- Issue date: 2017 Nov
- Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation.
- Authors: Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A
- Issue date: 2020 Sep